• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors

    10/19/21 7:00:00 AM ET
    $FSTX
    $PIRS
    $TTOO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $FSTX alert in real time by email

    Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company's Board of Directors. Ms. Deptula-Hicks is a highly regarded financial executive with decades of experience working with and advising private and public life sciences companies.

    "We are excited to welcome Darlene to our Board of Directors at this important time in our company," said David de Graaf, Chief Executive Officer of Abcuro. "Darlene brings an impressive, thirty-year track record working with both publicly traded and venture-backed life sciences companies to Abcuro. Her insights will be invaluable as we continue to advance the clinical development of ABC008 and expand our therapeutic pipeline. We look forward to working with Darlene in developing capital market options and potential partnerships."

    Ms. Deptula-Hicks is recognized for her breadth of expertise in growth strategies and success at capital raising and initial public offerings (IPO). She operates Crimson Advisors, LLC, a strategic financial consulting services company and currently serves as the Chief Financial Officer of F-star Therapeutics, Inc. (NASDAQ:FSTX) which she took public in 2020. She provides strategic financial and business direction and leadership on long-term strategies and decisions affecting the future financial performance of organizations including capital formation, commercialization, strategy and M&A. Previously, she was Chief Financial Officer of Northern Biologics, Inc., and T2 Biosystems, Inc. (NASDAQ:TTOO). She also served as Senior Vice President and Chief Financial Officer of Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) which she also took public. Ms. Deptula-Hicks received her M.B.A. from Rivier University and B.S in accounting from Southern New Hampshire University.

    "I am excited to join Abcuro's Board and help further grow the company as they develop potentially life-changing medicines," said Ms. Deptula-Hicks. "I look forward to contributing to Abcuro's success and bringing value to investors, potential partners and of course, patients."

    About ABC008

    ABC008 is a first-in-class anti-KLRG1 antibody capable of selectively depleting highly cytotoxic T cells, while sparing regulatory and central memory T cells. ABC008 has been designed to treat diseases mediated by highly cytotoxic T cells, including the autoimmune muscle disease inclusion body myositis (IBM), T cell large granular lymphocytic leukemia (T-LGLL), and other mature T cell malignancies. The US Food and Drug Administration (FDA) has granted Orphan Drug Designation to ABC008 for the treatment of IBM.

    About Abcuro

    Abcuro is a clinical stage biotechnology company developing first-in-class immunotherapies for autoimmune diseases and cancer through precise modulation of highly cytotoxic T and NK cells. The company's lead program is ABC008, which is currently in clinical trials for inclusion body myositis (IBM). ABC008 is also advancing into clinical trials for additional autoimmune disease indications. The company is also developing ABC015 to selectively activate highly cytotoxic T and NK cells for treating cancer. For more information, visit abcuro.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005035/en/

    Get the next $FSTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $FSTX
    $PIRS
    $TTOO

    CompanyDatePrice TargetRatingAnalyst
    F-star Therapeutics Inc.
    $FSTX
    7/15/2022$35.00 → $7.00Buy → Neutral
    H.C. Wainwright
    T2 Biosystems Inc.
    $TTOO
    2/18/2022$0.70Neutral → Buy
    Alliance Global Partners
    F-star Therapeutics Inc.
    $FSTX
    11/18/2021$15.00Buy
    Ladenburg Thalmann
    F-star Therapeutics Inc.
    $FSTX
    8/17/2021$39.00 → $35.00Outperform
    SVB Leerink
    F-star Therapeutics Inc.
    $FSTX
    7/8/2021$39.00Outperform
    SVB Leerink
    More analyst ratings

    $FSTX
    $PIRS
    $TTOO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • T2 Biosystems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results

      LEXINGTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced preliminary unaudited financial and operational results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 and Recent Commercial Highlights (unaudited) Achieved record product revenues of $2.3 million for the fourth quarter of 2024 and $8.3 million for the full-year 2024, representing increases of 37% and 23% respectively, compared to the prior year period, driven by record sepsis test sales.Executed contracts for 27 T2Dx® Instruments in 2024, including

      1/7/25 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Announces Sale of Four T2Dx Instruments to Existing European Distributor

      LEXINGTON, Mass., Dec. 18, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the sale of four T2Dx® Instruments to its European (EU) distributor that represents multiple EU counties, demonstrating commercial expansion and increased international market penetration. The multiple instrument sale demonstrates commercial expansion to enable increased utilization of the T2Bacteria® Panel, the T2Candida® Panel, and the T2Resistance® Panel. The target hospitals for the new instruments include: Selling a second T2Dx Instrument to a major reference hospital to expand "same st

      12/18/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems Achieves Key Milestone with 250,000th Novel Sepsis Test Shipped Globally

      LEXINGTON, Mass., Dec. 17, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has surpassed the shipment of 250,000 sepsis tests, marking a significant milestone that underscores the growing customer adoption of the Company's direct-from-whole-blood technology. A meta-analysis of 14 controlled studies, published in a peer-reviewed medical journal, compared T2 Biosystems' sepsis tests to blood culture-based diagnostics, and showed that T2 Biosystems' products provided: faster time to detection (e.g., species identification 77 hours faster), faster targeted therapy (

      12/17/24 9:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $FSTX
    $PIRS
    $TTOO
    Financials

    Live finance-specific insights

    See more
    • T2 Biosystems Announces Third Quarter 2024 Financial Results

      LEXINGTON, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the "Company"), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced financial and operational results for the third quarter ended September 30, 2024. Recent Financial and Commercial Highlights Achieved third quarter total revenue of $2.0 million, representing an increase of 34% compared to the prior year period.Achieved sepsis test panel revenue of $1.4 million, representing an increase of 34% compared to the prior year period, driven by increased U.S. T2Bacteria® Panel revenue.Executed contracts for 11 T2Dx® Instruments during the third quar

      11/14/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Report Third Quarter 2024 Financial Results and Business Updates on November 14, 2024

      LEXINGTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the third quarter 2024 and business updates after market close on Thursday, November 14, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 877-545-0320

      11/5/24 8:00:00 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • T2 Biosystems to Host Business Update Call on October 10, 2024

      LEXINGTON, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will host a business update call to provide additional details on recent developments after market close at 4:30pm ET on Thursday October 10, 2024. On the call management also plans to address select questions from shareholders that can be submitted in advance to the investor relations team at [email protected]. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the

      10/8/24 4:05:00 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $FSTX
    $PIRS
    $TTOO
    SEC Filings

    See more
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/4/25 5:47:15 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form NT 10-K filed by T2 Biosystems Inc.

      NT 10-K - T2 Biosystems, Inc. (0001492674) (Filer)

      4/1/25 9:00:30 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by T2 Biosystems Inc.

      8-K - T2 Biosystems, Inc. (0001492674) (Filer)

      2/20/25 9:00:24 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $FSTX
    $PIRS
    $TTOO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • F-star Therapeutics downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded F-star Therapeutics from Buy to Neutral and set a new price target of $7.00 from $35.00 previously

      7/15/22 7:26:02 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • T2 Biosystems upgraded by Alliance Global Partners with a new price target

      Alliance Global Partners upgraded T2 Biosystems from Neutral to Buy and set a new price target of $0.70

      2/18/22 10:16:52 AM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Ladenburg Thalmann resumed coverage on F-star Therapeutics with a new price target

      Ladenburg Thalmann resumed coverage of F-star Therapeutics with a rating of Buy and set a new price target of $15.00

      11/18/21 9:22:57 AM ET
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    $PIRS
    $TTOO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Liebman Seymour

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:58:44 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Chief Commercial Officer Giffin Brett A.

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:55:13 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Adams Laura Lee

      4 - T2 Biosystems, Inc. (0001492674) (Issuer)

      1/2/25 6:46:12 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care

    $FSTX
    $PIRS
    $TTOO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Geraghty James A bought $1 worth of Series F Preferred Stock (1 units at $1.00) (SEC Form 4)

      4 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Issuer)

      10/28/24 5:18:29 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Adar1 Capital Management, Llc bought $92,326 worth of shares (6,000 units at $15.39) (SEC Form 4)

      4 - PIERIS PHARMACEUTICALS, INC. (0001583648) (Issuer)

      8/12/24 6:48:13 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $FSTX
    $PIRS
    $TTOO
    Leadership Updates

    Live Leadership Updates

    See more
    • Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer

      WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p

      10/17/24 7:30:00 AM ET
      $LFCR
      $LGND
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors

      Avacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company developing innovative, targeted cancer treatments and powerful diagnostics, today announced the appointment of Darlene Deptula-Hicks, MBA as a Non-Executive Director of the Company's Board of Directors, effective 26 June 2024. Ms. Deptula-Hicks is a highly accomplished financial executive with decades of experience working with and advising private and public life sciences companies. Shaun Chilton, Chairman of the Board of Avacta, commented: "Avacta is at a pivotal time in its e

      7/8/24 8:15:00 AM ET
      $PIRS
      $TTOO
      $FSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical/Dental Instruments
    • Levicept Appoints Eliot Forster as CEO

      Leadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, today announces the appointment of Eliot Forster as CEO. Founder and inventor of LEVI-04, Simon Westbrook, is to take the role of CSO. Eliot brings more than thirty years of experience in the biotech and pharmaceutical sectors, with considerable experience in deal making and finance. His appointment strengthens the Levicept leadership team as the company matur

      11/30/23 4:00:00 AM ET
      $IMCR
      $IMTX
      $PLX
      $FSTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $FSTX
    $PIRS
    $TTOO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

      SC 13G/A - PALVELLA THERAPEUTICS, INC. (0001583648) (Subject)

      12/17/24 5:42:35 PM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by T2 Biosystems Inc.

      SC 13G - T2 Biosystems, Inc. (0001492674) (Subject)

      11/14/24 3:38:45 PM ET
      $TTOO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Pieris Pharmaceuticals Inc.

      SC 13G/A - PIERIS PHARMACEUTICALS, INC. (0001583648) (Subject)

      11/14/24 9:07:46 AM ET
      $PIRS
      Biotechnology: Pharmaceutical Preparations
      Health Care